Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia

NCT04554056 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.

NCT NCT04554056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04554056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
September 21, 2020
Completion date
November 5, 2022
Enrollment
586 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female